Cent Eur J Public Health 2008, 16(1):26-28 | DOI: 10.21101/cejph.a3439

Participation in Pharmaceutical Costs and Seniors' Access to Medicines in the Czech Republic

Jana Davidová, Natasa Ivanovic, Lenka Práznovcová
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Czech Republic

Objectives: Analysis of participation in drug costs by seniors in the Czech Republic in connection with seniors' access to pharmacotherapy.

Materials and methods: Quota-sampled guided interview with 450 respondents visiting pharmacy; ratio of men and women approximately 1:2; age over 60 years; 3 regions of the Czech Republic.

Results: Respondent's income was retirement pension in 80 %. More than 55% of respondents did not reach the official state average. Respondents used altogether 1,650 medicines on physician's prescription in the last four weeks. Overall co-payment for medicines was 38,778 CZK, i.e. 86 CZK per patient. Only 27% of respondents used fully reimbursed products. Respondents used together 273 OTC drugs (over-the-counter drugs, e.g. non prescription drugs) in value of 16,540 CZK, i.e. 37 CZK per patient. Average respondent spent on medicines 123 CZK in the last four weeks, i.e. 1.5% of the official state average income. There were respondents, about 10%, searching for the level of co-payment in several pharmacies and more than 8% of respondents had to refuse dispensation of medicines due to co-payment.

Conclusions: Our study demonstrates that there are patients who may fail to gain access to medication due to co-payment in the Czech Republic. The financial participation in health care costs is generally low in the Czech Republic (8.8% of total health expenditures) but there were differences in co-payment levels in patients ranging from 1 CZK to thousands CZK.
In our opinion problem might be in the absence of any instrument limiting the highest individual participation as it is for example in 12-month period in Sweden. In our study co-payments were lower in smaller communities that may be due to better communication between physicians and patients or physicians and pharmacists. We found a critical ethical problem in different levels of co-payment of concrete product.

Keywords: seniors, Czech Republic, pharmaceutical costs, participation in costs, co-payment, access to pharmacotherapy

Received: July 3, 2007; Revised: October 31, 2007; Accepted: October 31, 2007; Published: March 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Davidová J, Ivanovic N, Práznovcová L. Participation in Pharmaceutical Costs and Seniors' Access to Medicines in the Czech Republic. Cent Eur J Public Health. 2008;16(1):26-28. doi: 10.21101/cejph.a3439. PubMed PMID: 18459476.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Economic information on health care 2003. Prague: Institute of Health Information and Statistics of the Czech Republic; 2004.
    2. Czech health statistics yearbook 2004. Prague: Institute of Health Information and Statistics of the Czech Republic; 2005.
    3. Rokosová M, Háva P, Schreyögg J, Busse R. Health care systems in transition: Czech Republic. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2005.
    4. Organisation for Economic Co-operation and Development [homepage on the Internet]. OECD in figures - 2005 edition. Health spending and resources [cited 2006 Feb 5]. Available from: http://www.oecd.org/document/62/0,3343,en_2649_34863_2345918_1_1_1_1,00.html.
    5. Petrova GI. Monitoring of national drug policies - regional comparison between Bulgaria, Romania, Macedonia, Bosnia Herzegovina. Cent Eur J Public Health. 2001 Nov;9(4):205-13.
    6. Czech health statistics yearbook 2003. Prague: Institute of Health Information and Statistics of the Czech Republic; 2004.
    7. Money income, expenditure and consumption according to the Household Budget Survey 2004. Prague: Czech Statistical Office; 2005.
    8. Public Health Insurance, as amended Act of 1997, Pub. L. No. 48/1997 Coll. Czech Republic (Mar 28, 1997). (In Czech.)
    9. Code list of medicinal products: version 520/2004. Prague: General Health Insurance Fund of the Czech Republic; 2006. (In Czech.)
    10. Health care in the Czech Republic in statistical data 2004. Prague: Institute of Health Information and Statistics of the Czech Republic; 2005.
    11. World Health Organisation [homepage on the Internet]. Copenhagen: European health for all database [cited 2006 Feb 5]. Available from: http://data.euro.who.int/hfadb.
    12. Decree of the Ministry of Health, which determines medicines fully reimbursed from public health insurance and the extent of reimbursement for particular medicinal substances Act of 1997, Pub. L. No. 57/1997 Coll. Czech Republic (Mar 28, 1997). (In Czech.)
    13. Holčík J, Koupilová I. Defining and assessing health-related quality of life. Cent Eur J Public Health. 1999 Nov;7(4):207-9.
    14. Pharmaceutical BenefitsAct of 2003, Pub. L. No. SFS 2002:160. Sweden (Nov 4, 2003).
    15. Busse R, Riesberg A. Health care systems in transition: Germany. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2004.
    16. Stabilisation of Public Budgets Act of 2007, Parliamentary draft No. 222/2007. Czech Republic (Aug 31, 2007). (In Czech.)

    Return to the content